VA Benefits: Trump Shares Update on Psychedelic Drug Treatment for Veterans
Summary
President Donald Trump announced steps to expand psychedelic drug treatments for veterans with mental health issues like PTSD, traumatic brain injury, and depression. The Department of Health and Human Services recently received an important 1994 government document about ibogaine, a psychedelic drug, to help speed up research and approval for these treatments.Key Facts
- President Trump supports increasing access to psychedelic therapies for veterans with serious mental health conditions.
- The Department of Health and Human Services Secretary Robert F. Kennedy Jr. received the original 1994 investigational new drug application for ibogaine from the University of Miami.
- Ibogaine is a natural psychedelic compound from an African plant that may help treat PTSD, depression, and addiction.
- The Department of Veterans Affairs is expanding clinical trials on psychedelic treatments like psilocybin for veterans who have not responded to other therapies.
- In April, President Trump signed an executive order to speed up research and federal support, around $50 million, for psychedelic drug studies.
- These efforts aim to offer veterans more treatment options for mental illnesses that do not improve with traditional medicine.
- Ibogaine is still classified as a Schedule I substance in the U.S., meaning it is illegal and not approved for medical use yet.
- Experts say the expanded research could change how mental health is treated in veterans and others with difficult-to-treat conditions.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
